mk 0663 has been researched along with Inflammatory Bowel Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aujla, U; Bjarnason, I; Kvasnovsky, CL | 1 |
| Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S | 1 |
1 review(s) available for mk 0663 and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Observational Studies as Topic; Pain; Pyrazoles; Pyridines; Recurrence; Sulfonamides; Sulfones | 2015 |
1 trial(s) available for mk 0663 and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gastrointestinal Tract; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Pyridines; Rheumatic Diseases; Severity of Illness Index; Sulfones; Treatment Outcome | 2006 |